Adhesion Molecules on the Endothelium and Mononuclear Cells in Human Atherosclerotic Lesions

Allard C. van der Wal, Pranab K. Das,

Albert J. Tigges, and Anton E. Becker From the Department of Cardiovascular Pathology,

University of Amsterdam, Academic Medical Center, Amsterdam, The Netherlands

Atherosclerotic lesions show features of a cellmediated immune inflammatory process. From this viewpoint, the potential role of arterial endothelium in the recruitment of mononuclear cells (T lymphocytes and macrophages) was studied. The endothelium of diffuse intimal thickening (DIT) and atheromatous plaques (AP) in human coronary arteries and abdominal aortas was characterized for the expression of adhesion molecules ELAM-1, ICAM-1, and the major histocompatibility complex (MHC) class II antigens HLA-DR/DP. A marked increase in expression of ICAM-I and ELAM-I, and to a lesser extent HLA-DR/DP was observed on endothelial cells that were adjacent to subendothelial infiltrates of T lymphocytes $(CD3^+$, $CD11a^+$, HLA-DR/DP⁺) and macrophages (CD14⁺, CD11a⁺, CD11c⁺, HLA-DR/DP⁺). This contrasted with a lower or absent expression of these activation markers at sites without prominent inflammatory cell infiltrates. These findings could be demonstrated in DIT as well as in AP. The observations suggest that cytokines produced by the subintimal infiltrates may activate the endothelium in a similar way as is observed in the microvasculature at sites of immune inflammation. The expression of these activation markers in the microvasculature is associated with enhanced leukocyte adhesion, permeability for macromolecules, and procoagulant activity, features known to occur also in early experimental atherosclerosis. The findings therefore support the concept that arterial endothelium plays an active role in the recruitment of mononuclear cells in atherosclerotic lesions. (Am J Pathol 1992, 141: 1427-1433)

To this extent, the involvement of endothelial cells is considered to be important. This is based particularly on previous observations that cultured endothelium as well as endothelial cells of the microvasculature are known to become activated under the influence of the cytokine network. $6-13$ The activated endothelial cells gain new functional status in relation to leukocyte adherence, as well as to changes in permeability of macromolecules and in coagulation activation. These alterations have been observed also in cases of experimental atherosclerosis.¹⁴ These altered functions at the level of the microvasculature are known to be associated with the expression of newly defined adhesion molecules.^{10,12,13} Adhesion molecules can be identified with the use of immunohistochemical techniques.

For these reasons, the study of the activation state of endothelial cells, particularly with regard to the expression of adhesion molecules, in relation to the inflammatory cellular infiltrates in atherosclerotic lesions, has been undertaken.

Materials and Methods

Tissue Sampling

Arterial tissues were obtained from autopsies of 14 patients who died of cardiovascular diseases ($n = 10$) or neurologic diseases ($n = 4$). Exclusion criteria were immunologic diseases, sepsis, and pulmonary hypertension.

The ages of the patients ranged from 30 to 64 years (mean age, 58), and the material was sampled within 2 to 9 hours after death (mean time span, 5 hours). Selected tissues included segments of the left coronary artery (ring-shaped) and of the abdominal aorta (1 cm length). These were taken from sites that were macroscopically normal and from small elevated, but otherwise uncomplicated, plaques. In addition, five segments of pulmonary

It is currently acknowledged that atherosclerotic lesions contain an immune-mediated inflammatory reaction. $1-5$

Accepted for publication June 15, 1992.

Address reprint requests to Dr. A. E. Becker, Department of Cardiovascular Pathology, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam-Zuidoost, The Netherlands.

arteries (1 cm length) and aortic tissue from five infant autopsies (O to 4 years) was sampled. Immediately after sampling, the segments were snap-frozen in liquid nitrogen and stored at -70° C. Cryostat sections, stained with hematoxylin and eosin, were used to classify the lesions.

Immunohistochemical Techniques

Immuno-single staining was performed in a three-step indirect immunoperoxidase assay.¹⁵ Briefly, monoclonal antibodies (MAbs) were applied to $6-\mu$ frozen sections, followed by a second-step incubation with peroxidaselabeled rabbit anti-mouse immunoglobulin (Dakopatts, Glostrup, Denmark) and a third-step horseradish peroxidase-labeled swine anti-rabbit immunoglobulin (Dakopatts).

Peroxidase activity was visualized with 3-amino-9 ethylcarbazole (AEC), and the sections were faintly counterstained with hematoxylin.

Immuno-double staining was performed combining the detection of an unlabeled MAb and a fluorescein isothiocyanate (FITC)-labeled antibody, in which FITC served as a hapten.¹⁵ Briefly, the first unlabeled MAb was applied to the sections, followed by alkaline phosphatase-labeled goat anti-mouse immunoglobulin (Dakopatts). This reaction was terminated using normal mouse serum (blocking step). The FITC-labeled second MAb was applied, followed by incubation with rabbit anti-FITC immunoglobulin (Dakopatts) and subsequently coupled with peroxidase-conjugated swine-anti-rabbit immunoglobulin (Dakopatts). Finally, alkaline phosphatase was visualized with fast blue BB and the peroxidase with AEC.

The MAbs used are listed in Table 1, including their specificities relevant to the current study, appropriate dilution, sources, and selected references.^{13,16-19} For double-staining method, the following combinations were used: FVIII-RA/Leu-4, FVIII-RA/Leu-M3, FVIII-RA/HLA-DR, ICAM-1/Leu-4, ELAM-1/Leu-4, ICAM-1/Leu-M3, LFA-1/Leu-4, HLA-DR/Leu-4, HLA-DR/Leu-M3.

Control tissues for testing the specificity of the reactivity of the antibodies included the microvasculature of human noninflamed skin and human psoriatic skin, in accordance with a previous communication in this context.20

Sections of arterial tissue, treated in identical fashion but with an irrelevant MAb of the same isotype, were used as negative controls.

Results

The aortic and coronary artery segments were classified either as diffuse intimal thickening (DIT, flat fibrocellular thickening of the intima) or as atheromatous plaques (AP, raised lesions with a central core of necrotic lipid rich debris surrounded by a fibrocellular cap). The pulmonary artery and infant aortas showed only minimal intimal thickening. The number of specimens is shown in Table 2.

Subendothelial infiltrates (Figure 1A, B) were defined

Table 1. List of Antibodies Used for Immunohistochemistry

a, Dakopatts (Glostrup, Denmark); b, Becton and Dickinson (Mountain View, California, USA); c, Dr. D. 0. Haskard Royal Postgraduate Medical School (London, UK); d, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service (Amsterdam, The Netherlands).

Anatomic site	Histology	Total	Expression of activation markers on endothelium					Clusters of mononuclear
			ICAM-1	ELAM-1	HLA-DR	HLA-DP	F-VIII	cells
Coronary artery	דום AP	13 9	ο	ь	5		13 9	9/13 8/9
Abdominal aorta	דום AP	10 17	12	10	9		10 17	5/10 15/17
Pulmonary artery Infant aortas								

Table 2. 7he Number of Tissue Segments Studied and the Reactivity of the Endothelium with Anti-adhesion Molecules and Anti-MHC Class II Antibodies

as focal accumulations of T-lymphocytes (Leu 4⁺) and macrophages (Leu 3⁺).

Immunophenotype of Arterial Endothelium

The reactivity pattern of the endothelium, taken from different anatomic sites, using anti-adhesion molecules, is summarized in Table 2. Anti-FVIII-RA staining in most cases showed a continuous lining of endothelial cells in, but in a small number there were interruptions of staining. All the lesions showed anti-FVIII-RA reactivity.

With anti-adhesion molecules, a patchy staining was found, which ranged from a few scattered cells to areas of continuous lining. Anti-ELAM-1 binding was found in coronary arteries and aortas associated with DIT and AP, but more often in larger areas in AP.

Of all the tested activation markers, anti-lCAM-1 binding was observed most frequently and most abundantly in DIT and AP, in which the shoulders of the plaques were preferentially involved. Moreover, two of five infant aortas and two pulmonary arteries showed a faint anti-ICAM-1 staining. Anti-MHC class ¹¹ reactivity appeared to be the most variable marker in DIT as well as in AP, of which anti-HLA-DR staining was present more frequently than anti-HLA-DP staining. Using these anti-MHC class ¹¹ antibodies, the staining intensity of endothelial cells was much lower as compared with the strong reactivity of subendothelial mononuclear cells. In contrast, the staining intensity of anti-lCAM-1 was about the same or even stronger in endothelial cells. Reactivity with the different activation markers occurred at about the same localization in one and the same lesion, as demonstrated by serial sections (Figure 1C, D). Expression of activation markers related to subendothelial infiltrates.

Foci of activated endothelium, as identified by the above-mentioned MAbs, were screened for the presence of subendothelial clusters of T lymphocytes (Leu-4+) and macrophages (Leu-M3+). Only scattered lymphocytes and macrophages could be detected in the thin intimal layer of pulmonary arteries and infant aortas.

Segments of adult coronary arteries and abdominal

aortas showed prominent subendothelial clusters of mononuclear inflammatory cells in sections with DIT (14 of 23 cases) and in AP (23 of 26 cases). In AP, these infiltrates were located subendothelially in the fibrous cap and, most abundantly, in the shoulder region of the lesions. Here a low number was noticed scattered through the intima or deep in the plaques around the atheroma as foamy macrophages. The expression of activation markers on endothelium overlying subendothelial inflammatory infiltrates is shown in Figure 2.

In sections containing a subendothelial cellular infiltrate, an almost uniform, albeit patchy expression of ICAM-1 was found in DIT (92% of sections) and AP (86% of sections). Conversely, ICAM-1 expression was also found in lesions devoid of inflammatory infiltrates, but in a much lower number (41%). The expression of ELAM-1, HLA-DR, and HLA-DP molecules on endothelial cells, adjacent to infiltrates, was less common than ICAM-1 expression. The incidence in DIT was 64%, 50%, and 7%, respectively, and in AP, 65%, 56%, and 43%, respectively. Inflammatory infiltrates were absent and the expression of ELAM-1 and HLA-DP dropped to zero; the expression of HLA-DR dropped to 16%. In a selected number of cases the immuno-double staining (ICAM-l/ Leu 4, ELAM-1/Leu 4, ICAM-1/Leu M3) clearly visualized adherence and margination of T-cells and monocytes/ macrophages at sites of activated endothelial cells (Figure $1E$ through G).

Immunophenotype of the Subendothelial Infiltrates

The T lymphocytes and macrophages were characterized further with antibodies directed to the aforementioned adhesion molecules and activation markers (Table 1). There was a strong anti-HLA-DR expression of T cells and macrophages. Part of the overall staining positivity with anti-HLA-DR was accounted for by smooth muscle cells. The HLA-DR⁺ macrophages were identified by their coexpression of Leu-M3. In addition, most of these cells expressed HLA-DP molecules and CD-11a, CD-

11c, and ICAM-1, which resulted in a membrane-bound staining pattern of variable intensity. T lymphocytes showed a ring-shaped CD-11a (LFA-1) reactivity. Once related to the pan T-cell reactivity (Leu-4) of the infiltrates, approximately 50% of the T cells was considered to express LFA-1 positivity. Intimate contacts between lymphocytes and macrophages, expressing adhesion molecules, was apparent with the double-staining experiments (Fig. 1H, I; LfA-1/Leu-4, ICAM/Leu-4).

Discussion

In atherosclerotic lesions, inflammatory infiltrates, composed of activated T cells and macrophages, occur.³⁻⁵

The results of the current study indicate that arterial endothelium in the proximity of these infiltrates shows features of an activated state, as based on the expression of adhesion molecules (ELAM-1, ICAM-1) and to a lesser extent MHC-class ¹¹ molecules (HLA-DR/DP). Thus far, the expression of adhesion molecules ELAM-1 and ICAM-1 on endothelial cells related to atherosclerotic lesions has not yet been reported in humans. Recently, Cybulsky and Gimbrone²¹ detected a newly defined inducible adhesion molecule, expressed by arterial endothelial cells overlying foam cell lesions in rats, which they have called 'athero-ELAM." Cytokines produced by the subendothelial inflammatory cells are a likely source for activation of these endothelial cells. Indeed, the cytokines tumor necrosis factor α (TNF- α) and γ -interferon (γ -IFN) have recently been identified in atherosclerotic lesions by means of immunocytochemical techniques.^{3,22} In those reports, macrophages, lymphocytes, and smooth muscle cells were considered to produce these cytokines.

The current study seems to support this concept because an almost uniform expression of ICAM-1 was found in the endothelium overlying clustered inflammatory cells in DIT and AP.

The fact that ICAM-1 staining occurred also in sections without prominent inflammatory infiltrates, as well as in sections of some normal pulmonary arteries and infant aortas, may lead to a conclusion that the staining reflects the baseline expression of ICAM-1 in these instances.^{6,8} Nevertheless, ICAM-1 expression is markedly enhanced in cases of DIT and AP with clustered inflammatory infiltrates.

Intercellular adhesion molecule ICAM-1 uses LFA-1 (CD11a) as counterstructure. ICAM-1 on endothelium mediates the adhesion of LFA-1 positive mononuclear cells.¹⁹ LFA-1 is expressed by T lymphocytes in the lesions, and their presence therefore may point toward the involvement of the LFA-1/lCAM-1 receptor ligand pathway in the recruitment of T lymphocytes in these lesions. The CD11a and CD11c (P150, 95) receptors on monocytes/macrophages mediate the adhesion of these cells to endothelium. Both epitopes were found to be expressed on the monocytes/macrophages in the lesions. Although the ligand for the CD11c receptor on endothelium is still unknown.²³ we observed the adhesion and margination of monocytes preferentially at places of activated endothelium (ELAM-1⁺, ICAM-1⁺).

Not only endothelium, but also subendothelial macrophages, expressed ICAM-1. Because the receptor molecules LFA-1 and P150, 95, as well as an abundance of MHC class ¹¹ antigens, are expressed together in the clusters of T cells and macrophages, this finding emphasizes cellular immune reactions at the subendothelial level.

ELAM-1 is an adhesion molecule unique for endothelium and becomes up-regulated during activation. We found ELAM-1 expression in lesions with prominent infiltrates, but not in the arterial segments devoid of infiltrates. In vitro ELAM-1 mediates adhesion of polymorphonuclear cells,¹² and in vivo expression is generally associated with an active (granulomatous) inflammation, and delayed hypersensitivity and certain cytokine reactions in the skin.^{8,10} In our experiments we found only occasionally polymorphonuclear cells as identified with antielastase, which is in accordance with the observations of Jonasson et al,⁴ who demonstrated that among all cells involved in atherosclerotic plaques only 0.1% could be identified as polymorphonuclear. Recently, the ELAM-1 has been reported to be involved in cytokine-mediated adhesion of T cells, 24 identified as memory T cells. $25 \ ln$ vivo immunocytochemical experiments have demonstrated ELAM-1 expression in rheumatoid arthritis, a chronic inflammatory process.26

The expression of MHC class ¹¹ antigens of endothe-

lium HLA-DR and HLA-DP was less pronounced than that of the anti-adhesion molecules, and in contrast to the strong HLA-DR and HLA-DP reactivity of subendothelial mononuclear cells. Because MHC class ¹¹ antigens on endothelium generally are considered to bind processed antigens for T cell recognition, $⁷$ it seems unlikely that an-</sup> tigen presentation is a major function of the arterial endothelium in atherosclerosis. Nevertheless, the presence of activated inflammatory cells indicates an ongoing inflammatory reaction, with an almost certain interaction with the overlying endothelium.

Focal absence of endothelium, as judged by absence of anti-factor-VIII-RA staining was found in a limited number of atherosclerotic plaques with dense mononuclear infiltrates. This loss of endothelium has been observed also at the ultrastructural level²⁷ and in other immunocytochemical studies.28 The spotty loss of endothelial identification could, of course, be due to an artifact secondary to autolysis or histologic processing. Conversely, one may speculate also, purely on theoretical grounds, that such endothelial cell loss could be due also to cytotoxic effects of locally produced cytokines (mainly TNF).²⁹

The results of this study indicate that the endothelium synthesizes adhesion molecules at sites of atherosclerotic lesions associated with subendothelial inflammatory infiltrates. The analogy with the endothelium of the microvasculature, $6-8$ and with observations in experimental atherosclerosis.^{14,21} suggests that the arterial endothelium is actively involved in the recruitment of mononuclear cells. In vivo studies of endothelial cell adhesion molecules are needed to verify whether this phenomenon contributes to progression or regression of lesions.

Note Added in Proof

After submitting the manuscript, at the request of one reviewer, we have studied the reactivity of endothelium with a second anti-ELAM antibody. Segments of coronary and carotid arteries obtained at autopsy that contained atherosclerotic plaques were used. Single staining experiments were carried out with a commercially available anti-ELAM-1 antibody, clone ENA-1 (Sanbio BV, Uden, The Netherlands). This antibody has been demonstrated to react with human endothelial cells activated with TNF and IL-1.^{30,31} Positive staining of endothelial cells with this antibody was obtained in a similar manner as described with the anti-ELAM-1 antibody 1.2B6.

Acknowledgment

The authors thank Dr. Haskard for supplying the monoclonal antibodies anti-ELAM-1 and anti-ICAM-1.

References

- 1. Hansson GK, Jonasson L, Seifert PA, Stemme S: Immune mechanisms in atherosclerosis. Arteriosclerosis 1989, 9: 567-578
- 2. Munro JM, Cotran RS: The pathogenesis of atherosclerosis: atherogenesis and inflammation. Lab Invest 1988, 58:249- 261
- 3. Hansson GK, Holm J, Jonasson L: Detection of activated T-lymphocytes in the human atherosclerotic plaque. Am ^J Pathol 1989, 13:169-175
- 4. Jonasson L, Holm J, Skalli 0, Bondjers G, Hansson GK: Regional accumulations of T cells, macrophages and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 1986, 6:131-138
- 5. Wal AC van der, Das PK, Bentz van de Berg D, Loos CM van der, Becker AE: Atherosclerotic lesion in humans: In situ immunophenotypic analysis suggesting an immune mediated response. Lab Invest 1989, 61:166-170
- 6. Cotran RS: New roles for endothelium in inflammation and immunity. Am ^J Pathol 1987, 129:407-413
- 7. Pober JS: Cytokine mediated activation of vascular endothelium. Physiology and pathology. Am ^J Pathol 1988, 133: 426-433
- 8. Munro JM, Pober JS, Cotran RS: Tumor necrosis factor in F-interferon induce distinct patterns of endothelial activation and associated leukocyte accumulation in skin of Papio Anubis. Am ^J Pathol 1989; 135:121-133
- 9. Pober JS, Gimbrone MA, Lapierre LA, Mendrick DL, Fiers W, Rothlein R, Springer TA. Overlapping patterns of activation of human endothelial cells by interleukin-1, tumor necrosis factor and immune interferon. J Immunol 1986, 137: 1893-1896
- 10. Pober JS, Grimbone MA, Cotran JS, Reiss CS, Burakoff SJ, Fiers W, Ault KA: la expression by vascular endothelium is inducible by activated T-cells and by human gammainterferon. ^J Exp Med 1983,157:1339-1353
- 11. Cotran RS, Gimbrone MA, Bevilaqua MP, Mendrick PL, Pober JS: Induction and detection of a human endothelial activation antigen in vivo. J Exp Med 1986, 164:661-666
- 12. Bevilaqua MP, Pober JS, Mendrick DL, Cotran RS, Gimbrone MA: Identification of an inducible endothelial leukocyte adhesion molecule. Proc NatI Acad Sci USA 1987, 84: 9238-9242
- 13. Dustin ML, Rothlein R, Bhan AR, Dinarello CA, Springer TA: Induction by IL-1 and interferon, tissue distribution, biochemistry and function of a natural adherence molecule (ICAM-1). J Immunol 1986,137:245-254
- 14. Ross R: The pathogenesis of atherosclerosis: An update. N Engl ^J Med 1986; 314:488-499
- 15. Loos CM van der, Das PK, Oord JJ van den, Houthoff HJ: Multiple immunoenzyme staining techniques: Use of fluorescinated, biotinylated and unlabeled monoclonal antibodies. J Immunol Methods 1989, 117:45-52
- 16. Wellicome SM, Thomhill MH, Pitzalis C, Thomas DS, Lanchbury JJS, Panayi GS, Haskard DO: A monoclonal antibody that detects a novel antigen on endothelial cells that is induced by tumor necrosis factor IL-1 or lipopolysaccharide. J Immunol 1990,144:2558-2565
- 17. Sanchez-Madrid F, Nagy JA, Robins E, Simon P, Springer TA: A human leukocyte differentiation family with distinct alpha subunit and a common beta subunit: The lymphocyte function associated antigen (LFA-1), the C3bi complement receptor (OKM1/MaC1) and the P150,95 molecule. J Exp Med 1983; 58:1785-1803
- 18. Marlin SD, Springer TA: Purified intercellular adhesion molecule (ICAM-1) is a ligand for lymphocyte function associated antigen ¹ (LFA-1). Cell 1987, 51:813-819
- 19. Arnaout MA, Lanier LL, Faller DV: Relative contribution of the leukocyte molecules Mol, LFA-1 and p150/95 (Leu M5) in adhesion of granulocytes and monocytes to vascular endothelium is tissue and stimulus specific. J Cell Physiol 1988, 137:305-309
- 20. Groves RW, Allen MH, Baker JNWN, Haskard DO, MacDonald DM: Endothelial leukocyte adhesion molecule-1 (ELAM-1) expression in cutaneous inflammation. Br J Dermatol 1991, 124:117-123
- 21. Cybulsky Ml, Gimbrone MA: Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991; 251:788-791
- 22. Barath P, Fishheim MC, Cao J, Berenson J, Helfant RH, Forrester JS: Detection and localization of tumor necrosis factor in human atheroma. Am ^J Cardiol 1990, 65:297-302
- 23. Springer TA: Adhesion receptors of the immune system. Nature 1990; 346:425-439
- 24. Graber N, Venkat Gopal T, Wilson D, Dawson Beall L, Polte T, Newman W: T-cells bind to cytokine activated endothelial cells via a novel inducible sialoglycoprotein and endothelial

leukocyte adhesion molecule-1. J Immunol 1990, 145:819-830

- 25. Shimizu Y, Shaw S, Graber N, Venkat Gopal T, Horgan KJ, Seventer GA van, Newman W: Activation dependent binding of human memory T cells to adhesion molecule ELAM-1. Nature 1991, 349:799-802
- 26. Koch AE, Burrows JC, Haine KG, Carlos TM, Harlan JM, Joseph S, Leibovich S. Immunolocalization of endothelial and leukocyte adhesion molecules in human rheumatoid and osteoarthritic synovial tissues. Lab Invest 1991, 64:313- 320
- 27. Davies MJ, Rowler PM, Woolf N: Surface ultrastructure of human coronary artery atherosclerotic plaques. ^J Pathol 1989, 157:171A
- 28. Gown AM, Tsukada T, Ross R. Human atherosclerosis: II. Immunocytochemical analysis of the cellular composition of human atherosclerotic lesions. Am J Pathol 1986, 125:191-207
- 29. Tracy KJ, Vlassara H, Cerami A: Peptide regulatory factors: Cachectin/tumour necrosis factor. Lancet 1989; 1:1122-1125
- 30. Leeuwenberg JFM, Jeunhomme TMAA, Buurman WA: Induction of an activation antigen on human endothelial cells in vitro. Eur J Immunol 1989, 19:715-720
- 31. Leeuwenberg JFM, Von Asmuth EKJ, Jeunhomme TMAA, Buurman WA: IFN- regulates the expression of the adhesion molecule ELAM-1 and IL-6 production by human endothelial cells in vitro. J Immunol 1990, 145:2110-2114